tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and CytomX Therapeutics (CTMX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTCResearch Report) and CytomX Therapeutics (CTMXResearch Report).

Irhythm Technologies (IRTC)

BTIG analyst Marie Thibault reiterated a Buy rating on Irhythm Technologies yesterday and set a price target of $178.00. The company’s shares closed last Thursday at $153.42, close to its 52-week high of $169.54.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 8.1% and a 34.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Pear Therapeutics.

Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $165.57, a 5.5% upside from current levels. In a report issued on August 1, J.P. Morgan also maintained a Buy rating on the stock with a $185.00 price target.

See today’s best-performing stocks on TipRanks >>

CytomX Therapeutics (CTMX)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on CytomX Therapeutics, with a price target of $4.00. The company’s shares closed last Thursday at $1.63, close to its 52-week low of $1.19.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.5% and a 34.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Currently, the analyst consensus on CytomX Therapeutics is a Moderate Buy with an average price target of $4.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IRTC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More